Cardiome Oxyprim is “approvable”
Executive Summary
Cardiome is assessing whether to continue development of Oxyprim (oxypurinol) for allopurinol-intolerant hyperuricemia following an FDA "approvable" letter. FDA Arthritis Advisory Committee expressed dissatisfaction with the protocol for the pivotal Phase II trial during a June 2 meeting (1"The Pink Sheet" June 7, 2004, p. 40)...